Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mindbio Therapeutics Corp. ( (TSE:MBIO) ) has issued an announcement.
MindBio Therapeutics has listed its common shares for trading on the OTCQB Market in the United States, a move that broadens access to US investors and aligns with the company’s push to position itself as a specialist in AI-powered predictive health technologies. The listing coincides with an extended US roadshow showcasing its voice-based drug and alcohol intoxication detection platform, which draws on more than 50 million data points and underpins the Booze AI app launched in 2025, as well as a planned enterprise platform aimed at workplace safety, call centres, mental health services and law enforcement, potentially opening new commercial channels and strengthening its foothold in the emerging voice analytics and health prediction market.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a Vancouver-based biotechnology company focused on clinical health research and the development of AI- and machine learning–driven health prediction technologies. Leveraging speech analytics, it has created a voice- and AI-powered model to detect and predict drug and alcohol intoxication for both consumer and enterprise applications, with targeted use cases in workplaces, law enforcement, mental health, and telehealth environments.
Average Trading Volume: 3,805
Technical Sentiment Signal: Hold
Current Market Cap: C$2.02M
For detailed information about MBIO stock, go to TipRanks’ Stock Analysis page.